Home

GARY S JACOB

CIK 1266802 · CHIEF DEVELOPMENT OFFICER · last filed 2026-07-23

GARY S JACOB is a CHIEF DEVELOPMENT OFFICER who has filed 55 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider was granted $4.9K of OKYO on Jul 23, 2026. Across all open-market trades the lifetime net is +$163.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $202.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$202.3K

Companies

10

Total Filings

55

Lifetime Open-Market Net

$163.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OKYO CHIEF DEVELOPMENT OFFICER 112,420 $1.64 $184.4K $50.0K 2 2026-07-23
Hepion Pharmaceuticals, Inc. (HEPA) Delisted Director 12 $0.08 $1 $19.9K 6 2024-02-21
Virpax Pharmaceuticals, Inc. (VRPX) Delisted Director 14 $0.00 $0 $23.8K 3 2022-01-05
CRDF Director 21,922 $0.82 $17.9K $49.7K 4 2021-06-15
Cardiff Oncology, Inc. (TROV) Delisted Director 148,954 — — $0 5 2019-06-24
Hepion Pharmaceuticals, Inc. (CTRV) Delisted Director — — — $0 2 2018-07-03
SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Executive Chairman 595,460 — — $20.0K 4 2018-06-18
Cardiff Oncology, Inc. (TROVW) Delisted Director — — — $0 7 2017-01-05
SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted Chief Executive Officer 396,999 — — $0 13 2016-06-27
CALLISTO PHARMACEUTICALS INC (KAL) Delisted Chief Executive Officer 1,474 $1.12 $1.7K $0 2 2007-10-25

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-23 OKYO Grant (A) +3,500 $4.9K EDGAR
2024-02-21 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) — $0 EDGAR
2022-05-19 OKYO Buy (P) +12,500 $50.0K EDGAR
2022-01-05 Virpax Pharmaceuticals, Inc. (VRPX) Delisted Grant (A) — $0 EDGAR
2021-06-15 CRDF Other (J) — $0 EDGAR
2021-05-20 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) — $0 EDGAR
2021-04-09 Virpax Pharmaceuticals, Inc. (VRPX) Delisted Grant (A) — $0 EDGAR
2021-03-23 CRDF Buy (P) +2,370 $24.7K EDGAR
2021-02-19 Virpax Pharmaceuticals, Inc. (VRPX) Delisted Buy (P) +3,500 $23.8K EDGAR
2020-12-01 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Buy (P) +12,000 $19.9K EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.